Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + Rituximab + Bendamustine in Waldenström's Macroglobulinemia
NCT06942507Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Open-label, single-arm trial of zanubrutinib in Waldenström's macroglobulinemia (WM), sponsored by Peking Union Medical College Hospital. Primary endpoint: Complete Response Rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT06942507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942507.